Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single-center analysis including 132 patients

Allgaier, Hans-Peter; Deibert, Peter; Olschewski, Manfred; Spamer, C.; Blum, Ulrich; Gerok, W.; Blum, Hubert E.

doi:10.1002/(sici)1097-0215(19981218)79:6<601::aid-ijc8>3.0.co;2-f

Cited by 112 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected these patients had lower survival rates. However, with minor differences depending on the group of patients selected and treatment modalities chosen, similar results were reported by others (Stuart et al, 1996;Allgaier et al, 1998;Bruix and Llovet, 2002;Herold et al, 2002;O'Suilleabhain et al, 2003).…”

Section: Discussionsupporting

confidence: 87%

“…In addition, the tumour stage and cirrhosis differed between these two groups leading to the observed differences in survival in contrast to studies published by others (Llovet et al, 2004). Similar to other reports, we saw a median survival of 24 months for the patients receiving TACE followed by PEI (Allgaier et al, 1998). A significant number of patients, who were not eligible for a combined treatment of TACE and PEI due to their stage of disease, were treated with TACE or PEI only.…”

Section: Discussionsupporting

confidence: 78%

“…Patients, who were not eligible for primary surgery, were treated according the algorithm shown in Figure 1. If possible, all patients underwent primarily TACE followed by PEI as previously suggested by Allgaier (Allgaier et al, 1998). If PEI was not possible after the first TACE, this treatment was repeated if needed until the tumour progressed despite treatment.…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Greten¹,

Papendorf

Bleck³

et al. 2005

Br J Cancer

174

101

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child -Pugh score B or C) and a score of 42. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 78%

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Greten¹,

Papendorf

Bleck³

et al. 2005

Br J Cancer

174

101

View full text Add to dashboard Cite

show abstract

“…Current treatment options include surgical resection, liver transplantation (2), and local ablative therapy, which are effective only in localized tumors (3). Therefore, identifying and establishing alternative approaches for treatment of HCC is quiet a challenge and of high interest.…”

Section: Introductionmentioning

confidence: 99%

Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma

et al. 2005

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis and one for which immunotherapy remains a viable option. Experimental tumor models have shown that regulatory T cells, a functionally unique subset of T cells, can suppress effective antitumor immune responses. This suppression might explain the poor outcome of some of the immunotherapy protocols currently being used. A better understanding of the role of regulatory T cells in HCC is important for design of future immunotherapy-based clinical protocols. We have studied regulatory T cells from 84 patients with HCC and 74 controls, including healthy donors, patients with chronic hepatitis B virus and hepatitis C virus infection and nonviral liver cirrhosis. Regulatory

show abstract

“…Current treatment options include surgical resection and liver transplantation (2), as well as local ablative therapy, which are effective only in localized tumors (3). In addition, HCC responds poorly to systemic chemotherapy; therefore, identifying and establishing novel approaches for the treatment of HCC is quite a challenge.…”

Section: Introductionmentioning

confidence: 99%

Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma

Korangy¹,

Ormandy²,

Bleck³

et al. 2004

Clinical Cancer Research

128

View full text Add to dashboard Cite

show abstract

Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single-center analysis including 132 patients

Cited by 112 publications

References 23 publications

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma

Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma

Contact Info

Product

Resources

About